Hi Audrey and Joan,
Funding IS hard to get, but so is the availability of personal funding to pay for the Herceptin even if you can find an onc willing, and if resources are scarce it really makes more sense to demonstrate what the benefit is, particularly since there is also the question whether to do just Herceptin or combine it with a taxane.
The recurrence statistic I think was in a 2005 article, either Sloan-Kettering or Mayo Clinic, and I could find it again if need be. It applied to the general population of bc patients, so I know the percentage in the first 5 years is quite a bit higher in the HER2 positive population. Joan, do you remember where you saw the 9% per year?
Has ANYONE seen any online predictor for recurrence/survival that factors in HER2 yet along with ER/PR status and node status? Or are oncologists still too weak-kneed to be that honest with us?
AlaskaAngel
|